134 related articles for article (PubMed ID: 9458330)
1. Abnormal transcripts of FHIT gene in thyroid cancer.
Chang TJ; Tsai TC; Wu YL; Yang HM; Chi CW; Yang AH; Lee CH
Oncol Rep; 1998; 5(1):245-7. PubMed ID: 9458330
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
4. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
5. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
[TBL] [Abstract][Full Text] [Related]
6. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
7. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
8. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines.
Simon B; Bartsch D; Barth P; Prasnikar N; Münch K; Blum A; Arnold R; Göke B
Cancer Res; 1998 Apr; 58(8):1583-7. PubMed ID: 9563464
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
11. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.
Bugert P; Wilhelm M; Kovacs G
Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948
[TBL] [Abstract][Full Text] [Related]
12. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
13. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the FHIT gene in human prostate cancer.
Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R
Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683
[TBL] [Abstract][Full Text] [Related]
15. [FHIT gene is abnormal in Chinese lung cancers].
Zhang J; Fu W; Zhang X
Zhonghua Yi Xue Za Zhi; 1999 Aug; 79(8):592-5. PubMed ID: 11715406
[TBL] [Abstract][Full Text] [Related]
16. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.
Yanagisawa K; Kondo M; Osada H; Uchida K; Takagi K; Masuda A; Takahashi T; Takahashi T
Cancer Res; 1996 Dec; 56(24):5579-82. PubMed ID: 8971157
[TBL] [Abstract][Full Text] [Related]
18. Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia.
Peters UR; Hasse U; Oppliger E; Tschan M; Ong ST; Rassool FV; Borisch B; Tobler A; Fey MF
Oncogene; 1999 Jan; 18(1):79-85. PubMed ID: 9926922
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.
Kisielewski AE; Xiao GH; Liu SC; Klein-Szanto AJ; Novara M; Sina J; Bleicher K; Yeung RS; Goodrow TL
Oncogene; 1998 Jul; 17(1):83-91. PubMed ID: 9671317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
